ABIONYX Pharma Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de ABIONYX Pharma disminuyan a un ritmo anual de 18.7%, mientras que sus ingresos anuales crecerán a un ritmo de 34.4% por año. Se espera que el BPA disminuya en un 4% al año.

Información clave

-23.4%

Tasa de crecimiento de los beneficios

-13.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	10.9%
Tasa de crecimiento de los ingresos	40.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

ENXTPA:ABNX - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	12	-7	-7	-7	1
12/31/2025	7	-9	-9	-9	1
12/31/2024	5	-6	-6	-6	1
6/30/2024	5	-3	-3	-3	N/A
3/31/2024	5	-3	-3	-3	N/A
12/31/2023	5	-4	-4	-4	N/A
9/30/2023	5	-4	N/A	N/A	N/A
6/30/2023	5	-4	-2	-2	N/A
3/31/2023	5	-4	-3	-3	N/A
12/31/2022	5	-4	-4	-3	N/A
9/30/2022	4	-5	N/A	N/A	N/A
6/30/2022	3	-6	-6	-6	N/A
3/31/2022	2	-6	-6	-6	N/A
12/31/2021	1	-6	-7	-7	N/A
9/30/2021	0	-5	N/A	N/A	N/A
6/30/2021	0	-4	-6	-5	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	N/A	-2	-1	-1	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	0	0	N/A
3/31/2020	N/A	0	-2	-2	N/A
12/31/2019	N/A	2	-4	-4	N/A
9/30/2019	0	1	-5	-5	N/A
6/30/2019	0	0	-6	-6	N/A
3/31/2019	0	-3	-6	-6	N/A
12/31/2018	0	-6	-6	-6	N/A
9/30/2018	0	-7	-6	-6	N/A
6/30/2018	N/A	-8	-7	-7	N/A
3/31/2018	N/A	-6	N/A	-8	N/A
12/31/2017	N/A	-5	N/A	-9	N/A
9/30/2017	N/A	-8	N/A	-11	N/A
6/30/2017	N/A	-11	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-25	N/A	-19	N/A
9/30/2016	N/A	-25	N/A	-19	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-20	N/A	-16	N/A
12/31/2015	N/A	-17	N/A	-14	N/A
9/30/2015	N/A	-13	N/A	-11	N/A
6/30/2015	N/A	-10	N/A	-8	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ABNX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ABNX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ABNX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (34.4% al año) de ABNX crezcan más rápidamente que los del mercado French (5.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (34.4% al año) de ABNX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ABNX se prevé que sea elevada dentro de 3 años.

ABIONYX Pharma Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to €0.14 loss

Consensus EPS estimates upgraded to €0.18 loss

Consensus EPS estimates upgraded to €0.23 loss

Price target increased to €5.50

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Recent updates

Consensus EPS estimates upgraded to €0.14 loss

First half 2024 earnings released

Does ABIONYX Pharma (EPA:ABNX) Have A Healthy Balance Sheet?

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

New minor risk - Share price stability

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

Is ABIONYX Pharma (EPA:ABNX) Using Too Much Debt?

Consensus EPS estimates upgraded to €0.18 loss

Consensus EPS estimates upgraded to €0.23 loss

First half 2023 earnings released

New minor risk - Shareholder dilution

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

Price target increased to €5.50

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Consensus revenue estimates fall by 22%

Insufficient new directors

Insufficient new directors

Consensus forecasts updated

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

Price target increased to €4.30

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

Will ABIONYX Pharma (EPA:ABNX) Spend Its Cash Wisely?

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

Investor sentiment improved over the past week

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

Investor sentiment improved over the past week

New 90-day low: €0.84

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

Investor sentiment improved over the past week

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

New 90-day high: €1.11

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

New 90-day low: €0.72

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento